anticoagulant

An arrow incrementally going up stairs before pointing straight up Blue background

Racing BMS and J&J, Bayer ties asundexian to 26% stroke decrease

The readout sets the bar for Bristol Myers Squibb and Johnson & Johnson in a blockbuster indication ahead of data on their rival factor XIa inhibitor.

Nick Paul Taylor Feb 5, 2026 12:15pm

Businessman climbing steps to pluck a star from the sky

Bayer's asundexian cuts stroke risk in phase 3

Nov 24, 2025 6:25am

Cartoon of businessmen standing around a broken target

BMS-J&J blood thinner fails phase 3, denting blockbuster hopes

Nov 14, 2025 8:10am

Glowing puzzle piece fitting into puzzle

CSL pays $117M for option on phase 3 blood clotting specialist

Sep 16, 2025 4:31am

pass the torch deal sell buy acquisition

Novartis inks $925M Anthos takeover to rejoin clot-busting race

Feb 11, 2025 5:21am

Graphic of a drop of blood made up of small data points and nodes

Regeneron anticoagulant bests enoxaparin, matches Eliquis

Dec 19, 2024 8:50am